Skip to content
OpenCapital
Get started

Citius Oncology, Inc. CTOR Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value at other companies

Merck & Co. logo
Merck & Co.MRK
——
Delcath Systems logo
Delcath SystemsDCTH
——
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
——

Other financials

Income statement

See full
Revenue$1.7M—
Gross profit$1.3M—
Operating income-$28.6M-283%
Net income-$26.6M-244%
EPS (diluted)-$0.27-145%

Balance sheet

See full
Cash & equivalents$2.6M+2,350,466%
Total equity$35.3M-1.0%
Total assets$100.7M+10.1%

Cash flow

See full
Operating cash flow-$3.8M-179%

Valuation

See full
Market cap$60.45M-74.7%

Returns & leverage

See full
Return on equity-119.9%+46.7pp
Current ratio0.5×+0.1×

Where this comes from

Reported directly by Citius Oncology, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue.

The official record: Citius Oncology, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Citius Oncology, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, intrinsic value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Citius Oncology, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, intrinsic value?
Citius Oncology, Inc. (CTOR) reported share-based compensation arrangement by share-based payment award, options, outstanding, intrinsic value of $5.39M in Q3 2026.